ArticleNeuro-oncology2011
Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma.
Article in Neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- The Prognostic Value of Amplification of theDiseases (Basel, Switzerland) · 2025Article
- Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level.Nature communications · 2024Article
- Survival-Related Genes on Chromosomes 6 and 17 in Medulloblastoma.International journal of molecular sciences · 2024Article
- A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma.Journal of molecular neuroscience : MN · 2024Article
- Whole-genome sequencing of extrachromosomal circular DNA of cerebrospinal fluid of medulloblastoma.Frontiers in oncology · 2022Article
- Article
- Identification and Characterization of Extrachromosomal Circular DNA in Human Placentas With Fetal Growth Restriction.Frontiers in immunology · 2021Observational
- High impact of miRNA-4521 on FOXM1 expression in medulloblastoma.Cell death & disease · 2019Article
- Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.Journal of neuro-oncology · 2018Article
- The ubiquitin-proteasome system and chromosome 17 in cerebellar granule cells and medulloblastoma subgroups.Cellular and molecular life sciences : CMLS · 2017Review
- A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.Oncotarget · 2015Article
- Analysis of chromosome 17 miRNAs and their importance in medulloblastomas.BioMed research international · 2015Review
- Noninvasive detection of glutamate predicts survival in pediatric medulloblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Cytogenetic prognostication within medulloblastoma subgroups.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Methylation-specific multiplex ligation-dependent probe amplification and its impact on clinical findings in medulloblastoma.Journal of neuro-oncology · 2014Article
- Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype.Cytotechnology · 2013Article
- Signaling pathway and molecular subgroups of medulloblastoma.International journal of clinical and experimental pathology · 2013Review
- Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.Journal of neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current risk stratification schemas for medulloblastoma, based on combinations of clinical variables and histotype, fail to accurately identify particularly good- and poor-risk tumors. Attempts have been made to improve discriminatory power by combining clinical variables with cytogenetic data. We report here a pooled analysis of all previous reports of chromosomal copy number related to survival data in medulloblastoma. We collated data from previous reports that explicitly quoted survival data and chromosomal copy number in medulloblastoma. We analyzed the relative prognostic significance of currently used clinical risk stratifiers and the chromosomal aberrations previously reported to correlate with survival. In the pooled dataset metastatic disease, incomplete tumor resection and severe anaplasia were associated with poor outcome, while young age at presentation was not prognostically significant. Of the chromosomal variables studied, isolated 17p loss and gain of 1q correlated with poor survival. Gain of 17q without associated loss of 17p showed a trend to improved outcome. The most commonly reported alteration, isodicentric chromosome 17, was not prognostically significant. Sequential multivariate models identified isolated 17p loss, isolated 17q gain, and 1q gain as independent prognostic factors. In a historical dataset, we have identified isolated 17p loss as a marker of poor outcome and 17q gain as a novel putative marker of good prognosis. Biological markers of poor-risk and good-risk tumors will be critical in stratifying treatment in future trials. Our findings should be prospectively validated independently in future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.